Post discusses a MRNA options trader who converted some call options (287.5 strikes) into lower strike puts (205 strikes), citing frustration from critics. No clear investment thesis or risk analysis provided beyond personal trade execution.

Poster expresses bullish conviction on MRNA, claiming to have accumulated shares and options at favorable prices while critics predicted the company's bankruptcy. They view recent price weakness as an opportunity rather than a fundamental concern.

Author is bearish on MRNA and holding a short position targeting $150, expecting the stock to decline significantly. Key risk is potential margin call if the stock continues rising instead.

The author criticizes portfolio managers for creating market volatility through constant sector rotation and risk mismanagement rather than actually managing risk. Despite mixed economic data (higher PPI but stable yields and oil), indiscriminate selling damaged market structure without establishing sustainable leadership, particularly affecting tech and growth stocks.

Post highlights CorMedix (CRMD) as a potential high-growth opportunity similar to Moderna's recent performance, projecting 1x-2x returns. Key risks include biotech volatility, clinical trial outcomes, regulatory approval uncertainty, and the speculative nature of comparing to past winners.

Post highlights CorMedix (CRMD) as a potential growth opportunity similar to Moderna's past performance, suggesting a 1-2x upside setup. Key risks include biotech volatility, clinical trial outcomes, regulatory approval uncertainty, and the speculative nature of comparing to past outlier performers.

Post compares PRME's cure capabilities favorably to MRNA, though lacks detailed supporting evidence or clinical data. Key risks include unsubstantiated claims, biotech volatility, and clinical trial uncertainties.

PHIO is trading at $1 with early-stage Phase 1 cancer immunotherapy showing complete tumor responses, positioned as a potential acquisition target following Moderna's Phase 3 success and massive valuation spike. Key risks include typical biotech hazards: Phase 1 data rarely translates to later stages, tiny sample sizes, high failure probability, and extreme speculative nature of pre-Phase 2 plays.

Moderna's mRNA cancer vaccine breakthrough (melanoma trial success with KEYTRUDA) is driving interest in personalized cancer treatments, creating a downstream investment opportunity in genetic sequencing companies that will be needed to identify tumor genetic targets for each patient receiving these personalized vaccines. Key risks include clinical trial setbacks, regulatory delays, and whether genetic sequencing demand will materialize as expected.

Biohaven (BHVN) is positioned as a potential high-growth biotech play similar to Moderna's trajectory, with pipeline candidates and development potential. Key risks include clinical trial failures, regulatory setbacks, competitive pressure from larger pharma, and typical biotech execution risk.